Provision Cost

A provision of the US 21st Century Cures Act that gives an additional six months of exclusive marketing rights to companies whose drugs are approved to treat rare diseases will cost the federal government some $869 million between 2016 and 2025, reports Ed Silverman at Pharmalot.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.